Metabolic benefits of inhibition of p38α in white adipose tissue in obesity

PLoS Biol. 2018 May 11;16(5):e2004225. doi: 10.1371/journal.pbio.2004225. eCollection 2018 May.

Abstract

p38 has long been known as a central mediator of protein kinase A (PKA) signaling in brown adipocytes, which positively regulate the transcription of uncoupling protein 1 (UCP-1). However, the physiological role of p38 in adipose tissues, especially the white adipose tissue (WAT), is largely unknown. Here, we show that mice lacking p38α in adipose tissues display a lean phenotype, improved metabolism, and resistance to diet-induced obesity. Surprisingly, ablation of p38α causes minimal effects on brown adipose tissue (BAT) in adult mice, as evident from undetectable changes in UCP-1 expression, mitochondrial function, body temperature (BT), and energy expenditure. In contrast, genetic ablation of p38α in adipose tissues not only markedly facilitates the browning in WAT upon cold stress but also prevents diet-induced obesity. Consistently, pharmaceutical inhibition of p38α remarkably enhances the browning of WAT and has metabolic benefits. Furthermore, our data suggest that p38α deficiency promotes white-to-beige adipocyte reprogramming in a cell-autonomous manner. Mechanistically, inhibition of p38α stimulates the UCP-1 transcription through PKA and its downstream cAMP-response element binding protein (CREB), which form a positive feedback loop that functions to reinforce the white-to-beige phenotypic switch during cold exposure. Together, our study reveals that inhibition of p38α is able to promote WAT browning and confer metabolic benefits. Our study also indicates that p38α in WAT represents an exciting pharmacological target to combat obesity and metabolic diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / drug effects
  • Adipose Tissue / metabolism*
  • Animals
  • Cellular Reprogramming
  • Cold Temperature
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Diet, High-Fat
  • Drug Evaluation, Preclinical
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Mice
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase 14 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 14 / genetics
  • Mitogen-Activated Protein Kinase 14 / metabolism*
  • Obesity / metabolism*
  • Obesity / prevention & control
  • Phenotype
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Thermogenesis

Substances

  • Creb1 protein, mouse
  • Cyclic AMP Response Element-Binding Protein
  • Imidazoles
  • Pyridines
  • Cyclic AMP-Dependent Protein Kinases
  • Mitogen-Activated Protein Kinase 14
  • SB 203580

Grants and funding

Ministry of Science and Technology of China (grant number 2016YFA0500102). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ministry of Science and Technology of China (grant number 2016YFC1304905). Received by Hao Ying and Haibing Zhang. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Natural Science Foundation of China (grant number 31525012). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Natural Science Foundation of China (grant number 31600954). Received by Wei Liu. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Natural Science Foundation of China (grant number 31371189). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Natural Science Foundation of China (grant number 81570768). Received by Yu-cheng Wang. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Natural Science Foundation of China (grant number 81471016). Received by JJ Jiang. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. "Personalized Medicines—Molecular Signature-based Drug Discovery and Development," Strategic Priority Research Program of the Chinese Academy of Sciences (grant number XDA12040324). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. "Personalized Medicines—Molecular Signature-based Drug Discovery and Development," Strategic Priority Research Program of the Chinese Academy of Sciences (grant number XDA12020108). Received by Ruimin Huang. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One Hundred Talent Program of Chinese Academy of Sciences. Received by Ruimin Huang. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Chinese Academy of Sciences (grant number ZDBS-SSW-DQC-02). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Chinese Academy of Sciences (grant number ZDRW-ZS-2017-1). Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Chinese Academy of Sciences/State Administration of Foreign Experts Affairs International Partnership Program for Creative Research Teams. Received by Hao Ying. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.